| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension.
|
Clin Pharmacol Ther
|
2003
|
1.79
|
|
2
|
Clinical pharmacology of bosentan, a dual endothelin receptor antagonist.
|
Clin Pharmacokinet
|
2004
|
1.66
|
|
3
|
First-in-man safety and pharmacokinetics of synthetic ozonide OZ439 demonstrates an improved exposure profile relative to other peroxide antimalarials.
|
Br J Clin Pharmacol
|
2013
|
1.15
|
|
4
|
Macitentan: entry-into-humans study with a new endothelin receptor antagonist.
|
Eur J Clin Pharmacol
|
2011
|
1.01
|
|
5
|
Investigation of the mutual pharmacokinetic interactions between bosentan, a dual endothelin receptor antagonist, and simvastatin.
|
Clin Pharmacokinet
|
2003
|
0.95
|
|
6
|
Mutual pharmacokinetic interactions between bosentan and lopinavir/ritonavir in healthy participants.
|
Antivir Ther
|
2010
|
0.93
|
|
7
|
Safety, tolerability, pharmacokinetics, and pharmacodynamics of macitentan, an endothelin receptor antagonist, in an ascending multiple-dose study in healthy subjects.
|
J Clin Pharmacol
|
2013
|
0.90
|
|
8
|
Entry-into-humans study with tezosentan, an intravenous dual endothelin receptor antagonist.
|
J Cardiovasc Pharmacol
|
2002
|
0.86
|
|
9
|
Pharmacokinetics and pharmacodynamics of tezosentan, an intravenous dual endothelin receptor antagonist, following chronic infusion in healthy subjects.
|
Br J Clin Pharmacol
|
2002
|
0.85
|
|
10
|
Treatment of secondary pulmonary hypertension with bosentan and its pharmacokinetic monitoring in ESRD.
|
Am J Kidney Dis
|
2004
|
0.81
|
|
11
|
Influence of mild liver impairment on the pharmacokinetics of tezosentan, a drug excreted unchanged into bile.
|
Br J Clin Pharmacol
|
2004
|
0.80
|
|
12
|
Pharmacokinetics and pharmacodynamics of the urotensin-II receptor antagonist palosuran in healthy male subjects.
|
J Clin Pharmacol
|
2009
|
0.80
|
|
13
|
Comparison of the pharmacokinetics, pharmacodynamics and tolerability of tezosentan between caucasian and Japanese subjects.
|
Br J Clin Pharmacol
|
2006
|
0.77
|
|
14
|
Investigation of mutual pharmacokinetic interactions between macitentan, a novel endothelin receptor antagonist, and sildenafil in healthy subjects.
|
Br J Clin Pharmacol
|
2014
|
0.77
|
|
15
|
Pharmacokinetics, safety and tolerability of miglustat in the treatment of pediatric patients with GM2 gangliosidosis.
|
Mol Genet Metab
|
2009
|
0.77
|
|
16
|
Influence of liver cirrhosis on the pharmacokinetics, pharmacodynamics, and safety of tezosentan.
|
J Clin Pharmacol
|
2009
|
0.75
|